Abstract
Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.
Norihiro Nishimoto, Kazuyuki Yoshizaki, Keiji Maeda, Taro Kuritani, Hitoshi Deguchi, Bunzo Sato, Nobuyuki Imai, Masaki Suemura, Takahiro Kakehi, Nobuhiro Takagi and Tadamitsu Kishimoto
The Journal of Rheumatology July 2003, 30 (7) 1426-1435;
Norihiro Nishimoto
Kazuyuki Yoshizaki
Keiji Maeda
Taro Kuritani
Hitoshi Deguchi
Bunzo Sato
Nobuyuki Imai
Masaki Suemura
Takahiro Kakehi
Nobuhiro Takagi
In this issue
The Journal of Rheumatology
Vol. 30, Issue 7
1 Jul 2003
Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.
Norihiro Nishimoto, Kazuyuki Yoshizaki, Keiji Maeda, Taro Kuritani, Hitoshi Deguchi, Bunzo Sato, Nobuyuki Imai, Masaki Suemura, Takahiro Kakehi, Nobuhiro Takagi, Tadamitsu Kishimoto
The Journal of Rheumatology Jul 2003, 30 (7) 1426-1435;
Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.
Norihiro Nishimoto, Kazuyuki Yoshizaki, Keiji Maeda, Taro Kuritani, Hitoshi Deguchi, Bunzo Sato, Nobuyuki Imai, Masaki Suemura, Takahiro Kakehi, Nobuhiro Takagi, Tadamitsu Kishimoto
The Journal of Rheumatology Jul 2003, 30 (7) 1426-1435;